Igor M. Belyakov, M.D., Ph.D., D.Sc.
My primary interest in research is the immunology of host-pathogen interactions and the host immune responses to pathogens at mucosal sites. One major focus of my studies is mucosal immune responses against viral and bacterial infections, innate immunity at mucosal sites, and mucosal inflammation (IBD model). I am interested in clinical and basic research in immunology with the application to the pathogenesis of infectious disease and vaccines. My future studies will focus primarily on mucosal immune responses against viral and bacterial infections that are transmitted through mucosal surfaces (such as HIV-1, HSV, influenza, RSV, smallpox, Salmonella, and others), innate immunity, mucosal adjuvants, CD8+ T cells, MHC class I, mucosal DC and epithelial cells, and the mechanism of T cell trafficking to and among different mucosal sites. I will work on the development of novel nanoemulsion-based recombinant vaccines for viral and bacterial pathogens and will characterize immune correlates of protection. My laboratory will be developing targeted delivery of pharmaceuticals to inflamed mucosal tissue (IBD) and to cancerous cells. My research will be concentrated in basic research in immunology with applications to the pathogenesis of infectious disease and to vaccine development against viral and bacterial pathogens and cancer.
Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl P., Moss B., Strober W., & Berzofsky J.A., 1998. Mucosal Immunization with HIV-1 peptide vaccine induces mucosal and systemic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA, Vol.95, pp.1709-1714.
Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton C.D., Kelsall B.L., Strober W., Moss B., & Berzofsky J.A., 1998. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. Journal of Virology, Vol.72 (10), pp. 8264-8272.
Belyakov I.M., Ahlers J.D., Brandwein B.Y., Earl P., Kelsall B.L., Strober W., Moss B., & Berzofsky J.A., 1998. Local mucosal HIV-specific CD8+ cytotoxic T lymphocytes protect against mucosal transmission of recombinant virus expressing HIV-1 gp160. Enhancement of protection by local administration of IL-12. Journal of Clinical Investigation, Vol.102, pp.2072-2081.
Belyakov I.M., Moss B., Strober W., & Berzofsky J.A., 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA, Vol.96, pp.4512-4517.
Belyakov I.M., Ahlers J.D., Clements J.D., Strober W., & Berzofsky J.A., 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. Journal of Immunology, Vol.165, pp.6454-6462.
Belyakov I.M., Hel Z, Kelsall B, Kuznetsov V., Ahlers J.D., Nacsa J., Watkins D.I., Altman J, Woodward R, Markham P., Clements J.D., Franchini G., Strober W., & Berzofsky J.A., 2001. Mucosal AIDS Vaccine Reduces Disease and Viral Load in Gut Reservoir and Blood After Mucosal Infection of Macaques. Nature Medicine, Vol.7, pp.1320-1326.
Belyakov I.M., Wang J., Koka R., Ahlers J.D., Snyder J.T., Tse R., Cox J., Gibbs J.S., Margulies D., & Berzofsky J.A., 2001. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. European Journal of Immunology, Vol.31, pp. 3557-3566.
Berzofsky J.A., Ahlers J.D., & Belyakov I.M., 2001. Strategies for Designing and Optimizing New Generation Vaccines. Nature Reviews: Immunology, Vol.1 (3), pp.209- 219.
Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., Snyder J.S., Ahlers J.D., Franchini G., Moss B., & Berzofsky J.A., 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA, Vol.100 (16), pp.9458-9463.
Snyder J.T., Alexander-Miller M.A., Berzofsky J.A., & Belyakov I.M., 2003. Molecular mechanisms and biological significance of CTL avidity. Current HIV Research, Vol.1, pp.287-294.
Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M. & Berzofsky J.A., 2004. Transcutaneous immunization induces mucosal CTL and protective immunity by migration of primed skin dendritic cells. Journal of Clinical Investigation, Vol.113 (7), pp.998- 1007.
Belyakov I.M., & Berzofsky J.A., 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity, Vol.20 (3), pp.247-253.
Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh SK., Terabe M., & Belyakov I.M., 2004. Progress on new vaccine strategies for chronic viral infections. Journal of Clinical Investigation, Vol.114 (4), pp.450-462.
Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., Markham P.D., Pal P., Clements J.D., Lewis M.G., Strober W., Franchini G., & Berzofsky J.A., 2006. Impact of Vaccine-induced Mucosal High Avidity CD8+ CTL in Delay of AIDS-viral Dissemination from Mucosa. Blood, Vol.107 (8), pp. 3258-3264.
Belyakov I.M., Isakov D., Zhu Q., Dzutsev A., Klinman D., & Berzofsky J.A., 2006. Enhancement of CD8+ T cell Immunity in the Lung by CpG ODN Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine Against Lethal Poxvirus Infection Even in a CD4-Deficient Host. Journal of Immunology, Vol.177, pp. 6336-6343.
Belyakov I.M., Isakov D., Zhu Q., Dzutsev A. & Berzofsky J.A., 2007. A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques Against Simian/Human Immunodeficiency Viral Depletion of Mucosal CD4+ T cells. Journal of Immunology, Vol.178, pp.7211-7221.
Belyakov I.M., Kozlowski S., Mage M., Ahlers J.D., Boyd L.F., Margulies D.H. & Berzofsky J.A., 2007. Role of á3 domain of class I MHC molecules in the activation of high and low avidity of CD8+ cytotoxic T lymphocytes. International Immunology, Vol.19 (12); pp.1413-1420.
Belyakov I.M. & Ahlers J.D., 2008. Functional CD8+ CTL in Mucosal Sites and HIV Infection: Moving Forward toward a Mucosal AIDS Vaccine. Trends in Immunology, Vol.29(11), pp.574-585.
Belyakov I.M., Ahlers J.D., Nabel G.J., Moss B., & Berzofsky J.A., 2008.Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology, Vol.381(1); pp.106-115.
Belyakov I.M., & Ahlers J.D., 2009. What Role Does the Route of Immunization Play in Generation of Protective Immunity Against Mucosal Pathogens? Journal of Immunology, Vol.183(11), pp.6883-6892.
Belyakov I.M. & Ahlers J.D., 2011. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for induction of protective mucosal immune responses. Current Medical Chemistry, Vol.18(26), pp.3953-3962.
Isakov D, Dzutsev A, Berzofsky JA, & Belyakov IM., 2011. Lack of IL-7 and IL-15 signaling affects interferon-gamma production more than survival of small intestinal intraepithelial CD8 T cells. European Journal of Immunology (in press).